Jorey Chernett Purchases 12,000 Shares of Oncology Institute (NASDAQ:STLN) Stock

Oncology Institute, Inc. (NASDAQ:STLN) major shareholder Jorey Chernett purchased 12,000 shares of the stock in a transaction on Friday, August 14th. The stock was bought at an average price of $6.54 per share, for a total transaction of $78,480.00. Following the completion of the transaction, the insider directly owned 10,660,858 shares of the company’s stock, valued at approximately $69,722,011.32. This trade represents a 0.11% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Oncology Institute Stock Up 1.4%

Shares of NASDAQ STLN opened at $6.40 on Wednesday. Oncology Institute, Inc. has a 52-week low of $2.32 and a 52-week high of $7.05.

Analysts Set New Price Targets

Separately, Weiss Ratings initiated coverage on shares of Oncology Institute in a report on Thursday, August 6th. They set a “sell (d-)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Oncology Institute Company Profile

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.